All attention has been on biosimilar policy, infliximab and to a lesser extent insulin glargine, but the issue is moving so quickly it is hard to imagine the focus will not shift elsewhere - sooner rather than later. …
Latest Video
New Stories
-
Teams lining up again for the Rare Cancers Australia Kosi Challenge
January 31, 2025 - - Latest News -
Trump backs price negotiation power as health nominee faces contentious hearing
January 31, 2025 - - Latest News -
Sigma-Chemist Warehouse merger set to proceed following shareholder backing
January 31, 2025 - - Latest News -
President's nominee denies calling for seizure of pharmaceutical patents
January 30, 2025 - - Latest News -
GPs call on NSW Government to fund free Meningococcal B vaccine
January 30, 2025 - - Latest News -
New Zealand's Pharmac reconsiders proposed move to single oestradiol patch brand
January 30, 2025 - - Latest News -
QBiotics strengthens medical leadership with two senior appointments
January 28, 2025 - - Australian Biotech